{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:31:49Z","timestamp":1764937909533,"version":"build-2065373602"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"43","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8200105265","8227160979","82002766"],"award-info":[{"award-number":["8200105265","8227160979","82002766"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,11,11]]},"DOI":"10.1038\/s41388-025-03561-3","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T09:35:49Z","timestamp":1757496949000},"page":"4130-4144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7852-075X","authenticated-orcid":false,"given":"Lin","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengna","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2697-3604","authenticated-orcid":false,"given":"Feiquan","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-9528","authenticated-orcid":false,"given":"Qiulei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3296-0711","authenticated-orcid":false,"given":"Wenhan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-1301","authenticated-orcid":false,"given":"Guoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuewen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8424-5763","authenticated-orcid":false,"given":"Si","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0302-9998","authenticated-orcid":false,"given":"Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0005-9358","authenticated-orcid":false,"given":"Man","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"3561_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3561_CR2","unstructured":"Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019;30:672\u2013705."},{"key":"3561_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","volume":"9","author":"DL Richardson","year":"2023","unstructured":"Richardson DL, Eskander RN, O\u2019Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 2023;9:851\u20139.","journal-title":"JAMA Oncol"},{"key":"3561_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonzalez-Martin A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34:681\u201392.","journal-title":"Ann Oncol"},{"key":"3561_CR5","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2217\/fon-2023-0782","volume":"20","author":"A Gonzalez-Martin","year":"2024","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, et al. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary. Future Oncol. 2024;20:1531\u201344.","journal-title":"Future Oncol"},{"key":"3561_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol. 2023;41:609\u201317.","journal-title":"J Clin Oncol"},{"key":"3561_CR7","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12:2115\u201332.","journal-title":"Theranostics"},{"key":"3561_CR8","doi-asserted-by":"publisher","first-page":"m3773","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773.","journal-title":"BMJ"},{"key":"3561_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45693-2","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gao B, Zhang L, Wang X, Zhu X, Yang H, et al. Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nat Commun. 2024;15:1568.","journal-title":"Nat Commun"},{"key":"3561_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/s41375-024-02253-3","volume":"38","author":"CM Arends","year":"2024","unstructured":"Arends CM, Kopp K, Hablesreiter R, Estrada N, Christen F, Moll UM, et al. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer. Leukemia. 2024;38:1378\u201389.","journal-title":"Leukemia"},{"key":"3561_CR11","doi-asserted-by":"crossref","unstructured":"Awasthi S, Dobrolecki LE, Sallas C, Zhang X, Li Y, Khazaei S, et al. UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Rep Med. 2024;5:101834.","DOI":"10.1016\/j.xcrm.2024.101834"},{"key":"3561_CR12","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1158\/0008-5472.CAN-21-2409","volume":"82","author":"B Pellegrino","year":"2022","unstructured":"Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernandez A, Viaplana C, et al. Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification. Cancer Res. 2022;82:1646\u201357.","journal-title":"Cancer Res"},{"key":"3561_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1084\/jem.20071875","volume":"205","author":"K Petropoulos","year":"2008","unstructured":"Petropoulos K, Arseni N, Schessl C, Stadler CR, Rawat VP, Deshpande AJ, et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med. 2008;205:515\u201322.","journal-title":"J Exp Med"},{"key":"3561_CR14","first-page":"1389","volume":"7","author":"L Santiago","year":"2017","unstructured":"Santiago L, Daniels G, Wang D, Deng FM, Lee P. Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. Am J Cancer Res. 2017;7:1389\u2013406.","journal-title":"Am J Cancer Res"},{"key":"3561_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bbrc.2013.11.031","volume":"442","author":"W Kobayashi","year":"2013","unstructured":"Kobayashi W, Ozawa M. The transcription factor LEF-1 induces an epithelial-mesenchymal transition in MDCK cells independent of beta-catenin. Biochem Biophys Res Commun. 2013;442:133\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"3561_CR16","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.3390\/ijms24043961","volume":"24","author":"J Li","year":"2023","unstructured":"Li J, Zhao B, Yao S, Dai Y, Zhang X, Yang N, et al. Dermal papilla cell\u2011derived exosomes regulate hair follicle stem cell proliferation via LEF1. Int J Mol Sci. 2023;24:3961.","journal-title":"Int J Mol Sci"},{"key":"3561_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120941","volume":"308","author":"X Chen","year":"2022","unstructured":"Chen X, Tu J, Liu C, Wang L, Yuan X. MicroRNA-621 functions as a metastasis suppressor in colorectal cancer by directly targeting LEF1 and suppressing Wnt\/beta-catenin signaling. Life Sci. 2022;308:120941.","journal-title":"Life Sci"},{"key":"3561_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112091","volume":"143","author":"E Fakhr","year":"2021","unstructured":"Fakhr E, Zare F, Azadmanesh K, Teimoori-Toolabi L. LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan. Biomed Pharmacother. 2021;143:112091.","journal-title":"Biomed Pharmacother"},{"key":"3561_CR19","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/sj.bjc.6601265","volume":"89","author":"K Rask","year":"2003","unstructured":"Rask K, Nilsson A, Brannstrom M, Carlsson P, Hellberg P, Janson PO, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer. 2003;89:1298\u2013304.","journal-title":"Br J Cancer"},{"key":"3561_CR20","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1089\/scd.2014.0588","volume":"24","author":"AY Kwon","year":"2015","unstructured":"Kwon AY, Kim GI, Jeong JY, Song JY, Kwack KB, Lee C, et al. VAV3 overexpressed in cancer stem cells is a poor prognostic indicator in ovarian cancer patients. Stem Cells Dev. 2015;24:1521\u201335.","journal-title":"Stem Cells Dev"},{"key":"3561_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42850-x","volume":"14","author":"L Tao","year":"2023","unstructured":"Tao L, Zhou Y, Pan X, Luo Y, Qiu J, Zhou X, et al. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1\/2 and RAD51. Nat Commun. 2023;14:7430.","journal-title":"Nat Commun"},{"key":"3561_CR22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature24023","volume":"549","author":"N Arnoult","year":"2017","unstructured":"Arnoult N, Correia A, Ma J, Merlo A, Garcia-Gomez S, Maric M, et al. Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN. Nature. 2017;549:548\u201352.","journal-title":"Nature"},{"key":"3561_CR23","doi-asserted-by":"crossref","unstructured":"Meers MP, Bryson TD, Henikoff JG, Henikoff S. Improved CUT&RUN chromatin profiling tools. Elife. 2019;8:e46314.","DOI":"10.7554\/eLife.46314"},{"key":"3561_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.eururo.2019.07.015","volume":"76","author":"A Martini","year":"2019","unstructured":"Martini A, Sfakianos JP, Galsky MD. Conditionally reprogrammed patient-derived cells: a step forward towards personalized medicine?. Eur Urol. 2019;76:435\u20136.","journal-title":"Eur Urol"},{"key":"3561_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMra1806175","volume":"380","author":"M Li","year":"2019","unstructured":"Li M, Izpisua Belmonte JC. Organoids - preclinical models of human disease. N Engl J Med. 2019;380:569\u201379.","journal-title":"N Engl J Med"},{"key":"3561_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, de Witte CJ, Lohmussaar K, Valle-Inclan JE, Hami N, Kester L, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25:838\u201349.","journal-title":"Nat Med"},{"key":"3561_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6874","volume":"6","author":"M Petersson","year":"2015","unstructured":"Petersson M, Reuter K, Brylka H, Kraus A, Schettina P, Niemann C. Interfering with stem cell-specific gatekeeper functions controls tumour initiation and malignant progression of skin tumours. Nat Commun. 2015;6:5874.","journal-title":"Nat Commun"},{"key":"3561_CR28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/nrc2523","volume":"8","author":"WM Bonner","year":"2008","unstructured":"Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer. 2008;8:957\u201367.","journal-title":"Nat Rev Cancer"},{"key":"3561_CR29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","volume":"20","author":"R Scully","year":"2019","unstructured":"Scully R, Panday A, Elango R, Willis NA. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20:698\u2013714.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3561_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102555","volume":"8","author":"J Shao","year":"2021","unstructured":"Shao J, Yan Y, Ding D, Wang D, He Y, Pan Y, et al. Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O\u2019PROTAC): effective targeting of LEF1 and ERG. Adv Sci. 2021;8:e2102555.","journal-title":"Adv Sci"},{"key":"3561_CR31","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-18-1232","volume":"25","author":"SY Park","year":"2019","unstructured":"Park SY, Kim JY, Choi JH, Kim JH, Lee CJ, Singh P, et al. Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness. Clin Cancer Res. 2019;25:1415\u201329.","journal-title":"Clin Cancer Res"},{"key":"3561_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101811","volume":"39","author":"J Sun","year":"2021","unstructured":"Sun J, Huang X, Niu C, Wang X, Li W, Liu M, et al. aFGF alleviates diabetic endothelial dysfunction by decreasing oxidative stress via Wnt\/beta-catenin-mediated upregulation of HXK2. Redox Biol. 2021;39:101811.","journal-title":"Redox Biol"},{"key":"3561_CR33","doi-asserted-by":"publisher","first-page":"e2144942","DOI":"10.1001\/jamanetworkopen.2021.44942","volume":"5","author":"DM Cairns","year":"2022","unstructured":"Cairns DM, Dulko D, Griffiths JK, Golan Y, Cohen T, Trinquart L, et al. Efficacy of niclosamide vs placebo in SARS-CoV-2 respiratory viral clearance, viral shedding, and duration of symptoms among patients with mild to moderate COVID-19: a phase 2 randomized clinical trial. JAMA Netw Open. 2022;5:e2144942.","journal-title":"JAMA Netw Open"},{"key":"3561_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.790","volume":"12","author":"A Weiss","year":"2022","unstructured":"Weiss A, Delavenne E, Matias C, Lagler H, Simon D, Li P, et al. Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial. Clin Transl Med. 2022;12:e790.","journal-title":"Clin Transl Med"},{"key":"3561_CR35","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/1541-7786.MCR-18-1369","volume":"18","author":"M Xiao","year":"2020","unstructured":"Xiao M, Guo J, Xie L, Yang C, Gong L, Wang Z, et al. Let-7e suppresses DNA damage repair and sensitizes ovarian cancer to cisplatin through targeting PARP1. Mol Cancer Res. 2020;18:436\u201347.","journal-title":"Mol Cancer Res"},{"key":"3561_CR36","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1093\/nar\/gku296","volume":"42","author":"PA Vidi","year":"2014","unstructured":"Vidi PA, Liu J, Salles D, Jayaraman S, Dorfman G, Gray M, et al. NuMA promotes homologous recombination repair by regulating the accumulation of the ISWI ATPase SNF2h at DNA breaks. Nucleic Acids Res. 2014;42:6365\u201379.","journal-title":"Nucleic Acids Res"},{"key":"3561_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"3561_CR38","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1158\/1535-7163.MCT-12-0002","volume":"11","author":"YT Yo","year":"2012","unstructured":"Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MW, et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012;11:1703\u201312.","journal-title":"Mol Cancer Ther"},{"key":"3561_CR39","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1038\/onc.2014.277","volume":"34","author":"ML King","year":"2015","unstructured":"King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, et al. WNT7A\/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015;34:3452\u201362.","journal-title":"Oncogene"},{"key":"3561_CR40","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.gendis.2022.12.005","volume":"10","author":"L Huang","year":"2023","unstructured":"Huang L, Zhang J, Deng Y, Wang H, Zhao P, Zhao G, et al. Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer. Genes Dis. 2023;10:1687\u2013701.","journal-title":"Genes Dis"},{"key":"3561_CR41","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1097\/IGC.0000000000000506","volume":"25","author":"CL Walters Haygood","year":"2015","unstructured":"Walters Haygood CL, Arend RC, Gangrade A, Chettiar S, Regan N, Hassmann CJ, et al. Niclosamide analogs for treatment of ovarian cancer. Int J Gynecol Cancer. 2015;25:1377\u201385.","journal-title":"Int J Gynecol Cancer"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03561-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03561-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03561-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:02:28Z","timestamp":1760997748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03561-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":41,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2025,11,11]]}},"alternative-id":["3561"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03561-3","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"type":"print","value":"0950-9232"},{"type":"electronic","value":"1476-5594"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study followed the ethical principles of the Declaration of Helsinki. Informed consent was obtained from all participants before clinical specimens and information was collected, with approval from the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. Procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of Wuhan Youdu Biological Technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}